201 related articles for article (PubMed ID: 24144304)
1. PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum.
Strøm TB; Tveten K; Leren TP
Biochem J; 2014 Jan; 457(1):99-105. PubMed ID: 24144304
[TBL] [Abstract][Full Text] [Related]
2. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
3. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
Holla ØL; Cameron J; Berge KE; Ranheim T; Leren TP
BMC Cell Biol; 2007 Mar; 8():9. PubMed ID: 17328821
[TBL] [Abstract][Full Text] [Related]
4. Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation.
Benjannet S; Hamelin J; Chrétien M; Seidah NG
J Biol Chem; 2012 Sep; 287(40):33745-55. PubMed ID: 22875854
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Maxwell KN; Fisher EA; Breslow JL
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
[TBL] [Abstract][Full Text] [Related]
6. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Holla ØL; Strøm TB; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Feb; 99(2):149-56. PubMed ID: 19828345
[TBL] [Abstract][Full Text] [Related]
7. Sorting an LDL receptor with bound PCSK9 to intracellular degradation.
Leren TP
Atherosclerosis; 2014 Nov; 237(1):76-81. PubMed ID: 25222343
[TBL] [Abstract][Full Text] [Related]
8. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.
Gu HM; Adijiang A; Mah M; Zhang DW
J Lipid Res; 2013 Dec; 54(12):3345-57. PubMed ID: 24103783
[TBL] [Abstract][Full Text] [Related]
10. MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells.
Wang X; Berry E; Hernandez-Anzaldo S; Sun D; Adijiang A; Li L; Zhang D; Fernandez-Patron C
FEBS Lett; 2015 Feb; 589(4):490-6. PubMed ID: 25613181
[TBL] [Abstract][Full Text] [Related]
11. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.
Tveten K; Holla ØL; Cameron J; Strøm TB; Berge KE; Laerdahl JK; Leren TP
Hum Mol Genet; 2012 Mar; 21(6):1402-9. PubMed ID: 22156580
[TBL] [Abstract][Full Text] [Related]
12. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Cameron J; Holla ØL; Ranheim T; Kulseth MA; Berge KE; Leren TP
Hum Mol Genet; 2006 May; 15(9):1551-8. PubMed ID: 16571601
[TBL] [Abstract][Full Text] [Related]
13. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
[TBL] [Abstract][Full Text] [Related]
14. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.
Lo Surdo P; Bottomley MJ; Calzetta A; Settembre EC; Cirillo A; Pandit S; Ni YG; Hubbard B; Sitlani A; Carfí A
EMBO Rep; 2011 Dec; 12(12):1300-5. PubMed ID: 22081141
[TBL] [Abstract][Full Text] [Related]
16. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Zhang DW; Lagace TA; Garuti R; Zhao Z; McDonald M; Horton JD; Cohen JC; Hobbs HH
J Biol Chem; 2007 Jun; 282(25):18602-18612. PubMed ID: 17452316
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
[TBL] [Abstract][Full Text] [Related]
18. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
DeVay RM; Yamamoto L; Shelton DL; Liang H
PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor.
Zhang DW; Garuti R; Tang WJ; Cohen JC; Hobbs HH
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13045-50. PubMed ID: 18753623
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
